This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
. “On behalf of the long-term [care] industry, we welcome the decision by the FDA to approve emergency use authorization to expedite the distribution of a COVID vaccine,” said Mark Parkinson, president and CEO of the American Health Care Association and National Center for AssistedLiving.
. “On behalf of the long-term [care] industry, we welcome the decision by the FDA to approve emergency use authorization to expedite the distribution of a COVID vaccine,” said Mark Parkinson, president and CEO of the American Health Care Association and National Center for AssistedLiving.
Two widely anticipated new COVID-19 vaccines — from Johnson & Johnson and Novavax — appear to halt infections in places where more contagious variants are circulating, new trials show. The more infectious British variant was found to have caused about 50 percent of the cases in that trial, Novavax said.
million, will boost its vaccine rollout to now include health care workers, nursing home residents and staff, as well as those living in congregate settings such as assistedliving or shelters. Food and Drug Administration last week said it would stick with the two-shot dose backed by randomized clinical trials.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content